Canixin DHPPi/L

Dogs:
Common
(1 to 10 animals / 100
animals treated):
Injection site swelling
1,2,3
, Injection site oedema
2,3,4
Lethargy
Rare
(1 to 10 animals /
10,000 animals
treated):
Injection site pain
2,3
, Injection site pruritus
2,3
Hyperthermia
, Anorexia
Digestive tract disorders
(e.g. Diarrhoea
,
Vomiting
)
Very rare
(<1 animal / 10,000
animals treated,
including isolated
reports):
Hypersensitivity reaction (e.g. Anaphylaxis, Allergic
skin reaction such as Allergic oedema, Urticarial
erythema, Allergic pruritus)
1
(≤ 4 cm)
Transient
Resolves spontaneously within 1 to 2 weeks.
Slight diffuse
Appropriate symptomatic treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local representative
or the national competent authority via the national reporting system. See the
package leaflet for respective contact details.